The Future of Antibody Drugs

UBA matamab a mu 16 CD3 by specific that sounds pretty cool we've actually now presented that a couple of times presented asmo last year and we presented the single agent activity clearly clearly there's clinical benefit modest. We haven't yet seen the combination data but we're really excited to see you know where that's going into in that next generation of bi-specific antibodies potentially combined with PD-1 inhibitors. I think it's a drug that is going to potentially benefit our patients in the future any other new exciting areas CAR-T I tell you I can't believe we're going to have a CAR-T trial we actually have our first site open I just heard Oklahoma is